Publications by authors named "Erica B Bhavsar"
Article Synopsis
- Venetoclax-based therapy is a standard treatment for chronic lymphocytic leukemia (CLL), but how to manage patients after stopping it is unclear.
- A study involving 326 patients who discontinued venetoclax explored their responses to different treatments, focusing on overall response rate and progression-free survival.
- Results indicated that BTK inhibitors were highly effective for patients who had not previously received them, while less effective for those who had, and PI3K inhibitors provided limited benefit, highlighting the importance of treatment history when selecting post-venetoclax therapies.
Article Synopsis
- * A study compared 321 patients across the U.S. and U.K., analyzing demographics, treatment responses, and survival outcomes for both treatment approaches.
- * Results showed similar overall response rates and no significant differences in progression-free or overall survival between VENmono and VENcombo, suggesting both treatments are equally effective, though further studies are necessary for confirmation.
Genetic and epigenetic intra-tumoral heterogeneity cooperate to shape the evolutionary course of cancer. Chronic lymphocytic leukaemia (CLL) is a highly informative model for cancer evolution as it undergoes substantial genetic diversification and evolution after therapy. The CLL epigenome is also an important disease-defining feature, and growing populations of cells in CLL diversify by stochastic changes in DNA methylation known as epimutations.
View Article and Find Full Text PDFArticle Synopsis
- Recurrent mutations in the spliceosome, particularly in the SF3B1 component, are linked to several human cancers but their exact roles in cancer progression and treatment are not fully understood.
- SF3B1 mutations lead to common and tumor-specific splicing defects, primarily causing abnormal selection of the 3' splice sites, which impacts RNA splicing accuracy.
- Around 50% of mRNAs affected by these splicing errors are targeted for decay, resulting in reduced gene and protein expression, highlighting the functional importance of SF3B1 mutations in cancer.
Idelalisib is an inhibitor of the PI3Kδ isoform approved for treatment of patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma. Many patients develop gastrointestinal symptoms during idelalisib therapy; however, the pathologic effects of this drug have not been characterized. We identified 50 patients who received at least 3 months of idelalisib therapy.
View Article and Find Full Text PDF